15 results on '"Joerg Kraus"'
Search Results
2. Selecting a prospective test for early detection of diabetic polyneuropathy
- Author
-
Johannes Ebmer, Bertram Hölzl, A. Lee Dellon, Anja S. Ruhdorfer, Wolfgang Hitzl, Joerg Kraus, Mihran Azaryan, and Susanne Grinzinger
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Population ,Case-control study ,Gold standard (test) ,medicine.disease ,Asymptomatic ,Surgery ,Clinical trial ,Peripheral neuropathy ,Internal medicine ,Medicine ,medicine.symptom ,business ,education ,Prospective cohort study ,At-Risk Population - Abstract
Microneurolysis of entrapped peripheral nerve has the best chance of success when compression has not created significant axonal loss. The purpose of this study is to learn the best way to identify potential surgical candidates at the earliest time for intervention, by examining patients in a clinical setting using objective, electrodiagnostic nerve conduction studies (NCS), and subjective touch threshold studies, Semmes-Weinstein monofilaments (SWM) and Pressure-Specified Sensory Device™ (PSSD). Fifty-five patients with diabetic polyneuropathy over the age of 30 years were included. Neuropathy symptom score was the gold standard for statistical calculation, with a prevalence of 70%. In the symptomatic population, prevalence was 64% for NCS (n = 25), 59% for SWM (n = 43), and 88% for PSSD (n = 51). In the asymptomatic population, prevalence was 70% for NCS, 27% for SWM, and 92% for PSSD. It is concluded that the PSSD is the most sensitive device of those tested for identifying peripheral neuropathy in an at risk population of patients.
- Published
- 2015
- Full Text
- View/download PDF
3. Serial flow cytometric analyses of blood and cerebrospinal fluid in natalizumab-associated progressive multifocal leukencephalopathy with an excellent outcome
- Author
-
Katrin Oppermann, Joerg Kraus, Desiree van der Kleij, Johann Sellner, Shahrzad Afazel, Georg Pilz, Eugen Trinka, Elisabeth Haschke-Becher, Peter Wipfler, Theo Rispens, and Andrea Harrer
- Subjects
Pathology ,medicine.medical_specialty ,Natalizumab ,Cerebrospinal fluid ,Immunology and Microbiology (miscellaneous) ,business.industry ,Immunology ,Neuroscience (miscellaneous) ,Medicine ,Neurology (clinical) ,business ,medicine.drug - Published
- 2015
- Full Text
- View/download PDF
4. Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells
- Author
-
Elisabeth Haschke-Becher, Joerg Kraus, Wolfgang Hitzl, Peter Wipfler, Peter Strasser, Georg Pilz, Shahrzad Afazel, Katrin Oppermann, Max Einhaeupl, Eugen Trinka, and Andrea Harrer
- Subjects
Adult ,Male ,Immunology ,Integrin alpha4beta1 ,Biology ,Antibodies, Monoclonal, Humanized ,Blood–brain barrier ,Peripheral blood mononuclear cell ,Flow cytometry ,Multiple Sclerosis, Relapsing-Remitting ,Natalizumab ,Antigens, CD ,medicine ,Humans ,Immunology and Allergy ,medicine.diagnostic_test ,Multiple sclerosis ,Progressive multifocal leukoencephalopathy ,Antibodies, Monoclonal ,VLA-4 ,Middle Aged ,Flow Cytometry ,medicine.disease ,Natural killer T cell ,medicine.anatomical_structure ,Gene Expression Regulation ,Neurology ,Leukocytes, Mononuclear ,Female ,Neurology (clinical) ,medicine.drug - Abstract
Natalizumab interferes with immune cell migration into the central nervous system via blocking the alpha-4 subunit of very-late activation antigen-4 (VLA-4). Occurrence of rare but serious progressive multifocal leukoencephalopathy during prolonged natalizumab therapy of multiple sclerosis (MS) calls for a more detailed understanding of potential coeffects. We longitudinally studied alpha-4 and beta-1 surface levels on blood cells from 18 MS patients by flow cytometry. Expectedly, detectability of natalizumab-blocked alpha-4 was diminished on all investigated cell subsets. In addition, we report a concurrent and significant decrease of beta-1 surface levels on T-cells, B-cells, natural killer cells, and natural killer T cells, but not on monocytes. Uncovering secondary effects of natalizumab is mandatory to increase safety in MS therapy.
- Published
- 2011
- Full Text
- View/download PDF
5. Interferon-� 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis
- Author
-
Katrin Morgen, Manfred Kaps, Patrick Oschmann, Britta Engelhardt, Roland Bauer, Horst Traupe, Joerg Kraus, Nikolaos Chatzimanolis, Thomas Bregenzer, Benedikte S. Kuehne, Franz Blaes, Erwin Stolz, and Jasmin Tofighi
- Subjects
Adult ,Male ,Multiple Sclerosis ,Time Factors ,medicine.medical_treatment ,Cell ,Pharmacology ,Peripheral blood mononuclear cell ,Statistics, Nonparametric ,Flow cytometry ,Cell membrane ,medicine ,Humans ,Analysis of Variance ,medicine.diagnostic_test ,Chemistry ,Cell adhesion molecule ,Multiple sclerosis ,Cell Membrane ,Interferon beta-1b ,Interferon-beta ,medicine.disease ,medicine.anatomical_structure ,Cytokine ,Solubility ,Neurology ,Immunology ,Female ,Neurology (clinical) ,Cell Adhesion Molecules - Abstract
Adhesion molecules (AMs) are believed to regulate the transmigration of blood leukocytes across the blood-brain barrier (BBB), which is an essential step in the pathogenesis of multiple sclerosis (MS). Previous studies have investigated changes of the soluble forms of AM during interferon-beta1b (IFN-beta1b) treatment in MS patients. In this study, we analysed the influence of IFN-beta1b treatment on the cell surface bound forms of the AMs cICAM-1 and cICAM-3 on blood mononuclear cells (MNC). Sixty-eight patients with relapsing-remitting MS were enrolled in this open study; thirty of them were treated with IFN-beta1b. Blood samples were collected every three months over a period of 18 months. The expression levels of cell surface bound forms of AM on blood MNC were measured by two colour flow cytometry analysis. sVCAM-1, sICAM-1 and sICAM-3 were determined by ELISA. We found a short-term induction effect on the serum concentrations of sICAM-1 and sVCAM-1 after three months of IFN-beta1b treatment. The expression levels of cell surface bound AMs on blood MNC remained stable during treatment. Untreated MS patients, however, showed a continuous decrease in the expression of cell surface bound AM expression over 18 months. Stabilisation of the expression of cell surface bound AMs on blood MNC may indicate the beneficial effects of IFN-beta1b therapy in MS patients.
- Published
- 2004
- Full Text
- View/download PDF
6. Selecting a prospective test for early detection of diabetic polyneuropathy
- Author
-
Anja S, Ruhdorfer, Mihran, Azaryan, Joerg, Kraus, Susanne, Grinzinger, Wolfgang, Hitzl, Johannes, Ebmer, A Lee, Dellon, and Bertram, Hölzl
- Subjects
Adult ,Aged, 80 and over ,Male ,Neurologic Examination ,Neural Conduction ,Middle Aged ,Sensitivity and Specificity ,Early Diagnosis ,Diabetic Neuropathies ,Case-Control Studies ,Humans ,Female ,Prospective Studies ,Self Report ,Aged - Abstract
Microneurolysis of entrapped peripheral nerve has the best chance of success when compression has not created significant axonal loss. The purpose of this study is to learn the best way to identify potential surgical candidates at the earliest time for intervention, by examining patients in a clinical setting using objective, electrodiagnostic nerve conduction studies (NCS), and subjective touch threshold studies, Semmes-Weinstein monofilaments (SWM) and Pressure-Specified Sensory Device™ (PSSD). Fifty-five patients with diabetic polyneuropathy over the age of 30 years were included. Neuropathy symptom score was the gold standard for statistical calculation, with a prevalence of 70%. In the symptomatic population, prevalence was 64% for NCS (n = 25), 59% for SWM (n = 43), and 88% for PSSD (n = 51). In the asymptomatic population, prevalence was 70% for NCS, 27% for SWM, and 92% for PSSD. It is concluded that the PSSD is the most sensitive device of those tested for identifying peripheral neuropathy in an at risk population of patients.
- Published
- 2014
7. Prognostic Value of Soluble Tumor Necrosis Factor Receptors 1 and 2 in Multiple Sclerosis Patients Treated with Interferon Beta-1b
- Author
-
C. Laske, N. Chatzimanolis, Joerg Kraus, H. Diehl, J. Tofighi, H Traupe, B. S. Kühne, T. Bregenzer, Manfred Kaps, Patrick Oschmann, and R. Bauer
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pathology ,Multiple Sclerosis ,medicine.medical_treatment ,Gastroenterology ,Drug Administration Schedule ,Receptors, Tumor Necrosis Factor ,Central nervous system disease ,Disability Evaluation ,Antigens, CD ,Internal medicine ,medicine ,Humans ,Receptors, Tumor Necrosis Factor, Type II ,Prospective Studies ,Prospective cohort study ,Chemotherapy ,Dose-Response Relationship, Drug ,medicine.diagnostic_test ,business.industry ,Multiple sclerosis ,Interferon beta-1b ,Interferon beta-1a ,Brain ,Magnetic resonance imaging ,Interferon-beta ,Prognosis ,medicine.disease ,Magnetic Resonance Imaging ,Cytokine ,Neurology ,Female ,Neurology (clinical) ,business ,medicine.drug - Abstract
The objective of this study was to investigate the effect of interferon (IFN) beta-1b on the serum levels of soluble tumor necrosis factor receptor 1 (sTNF-R1) and sTNF-R2 in patients with multiple sclerosis (MS) in correlation with clinical and magnetic resonance image (MRI) activity. Serum samples were obtained every 3 months from 24 patients treated with 8 × 106 U of IFN beta-1b every other day (treatment group) and from 21 patients without any immunomodulatory therapy (control group) over a 15-month observation period. The cytokine receptor levels were assessed by ELISA. Cranial MRI was performed every 6 months to determine the burden of disease. In the treatment group, the MRI responders had significantly larger mean values for the area under the concentration-time curve of sTNF-R1 (p = 0.04) and sTNF-R2 (p = 0.01) when compared to the MRI nonresponders during the 15-month observation period. With regard to an increase in sTNF-R1 and -2 of more than 20% during the first 3 months of treatment, we observed a sensitivity of 33 and 58%, respectively, a specificity of 90 and 60%, respectively, and a positive predictive value of 80 and 64%, respectively, for MRI response during the 15-month observation period. A decrease in sTNF-R1 and -2 of more than 20% during the first 3 months of treatment had a sensitivity of 40 and 20%, respectively, a specificity of 100 and 100%, respectively, and a positive predictive value of 100 and 100%, respectively, for further MRI nonresponse (during the 15-month observation period). The present data suggest that assessment of sTNF-Rs may contribute to the identification of subgroups of patients who are likely to respond better than others to treatment with IFN beta-1b. This could help to establish a cost-effective prescription pattern for this expensive treatment, which is of importance for the future management of patients with MS.
- Published
- 2001
- Full Text
- View/download PDF
8. CRMP-5-Autoantibodies in Testicular Cancer Associated with Limbic Encephalitis and Choreiform Dyskinesias
- Author
-
Wolf Rüdiger Schäbitz, Joerg Kraus, Franz Blaes, Christoph Kellinghaus, and Darius G. Nabavi
- Subjects
medicine.medical_specialty ,Pathology ,Neurology ,Movement disorders ,medicine.diagnostic_test ,business.industry ,Limbic encephalitis ,Autoantibody ,Neurological examination ,medicine.disease ,Optic neuropathy ,Peripheral neuropathy ,medicine ,Neurology (clinical) ,Epileptic seizure ,medicine.symptom ,business - Abstract
Case Report A 40-year-old man presented with agitation, disorientation and optical hallucinations. He had a history of a malignant seminoma that had been treated with orchiectomy 7 years previously. He was admitted to a psychiatric ward of an outside general hospital but was transferred to our neurology service after he had had an epileptic seizure on admission day. At admission in our department, he was mildly disoriented. He also showed moderate amnestic symptoms and mild dysarthria, but neurological examination revealed no other abnormalities. A cranial magnetic resonance imaging study including contrast enhancement with gadolinium and a routine electroencephalogram were both normal. Cerebrospinal fluid (CSF) analysis showed 18 lymphocytes with no other abnormalities. He was treated with aciclovir until herpes simplex virus polymerase chain reaction proved to be negative, and additionally with ampicillin and ceftriaxone. Within 2 days he became increasingly agitated and suffered 2 more epileptic seizures necessitating anticonvulsive therapy with carbamazepine. Within the next few days, he became somnolent and developed severe swallowing and breathing difficulties. In addition, the patient developed Dear Sir, In addition to the well-known paraneoplastic-syndrome-associated antineuronal autoantibodies anti-Hu, anti-Yo and anti-Ri, a variety of different autoantibodies has been described in paraneoplastic neurological syndromes (PNS). One of these antibodies is an autoantibody binding to collapsin-response-mediating protein 5 (anti-CRMP-5) [1] , a phosphoprotein belonging to a group of proteins being important for axonal growth and also expressed in oligodendrocytes [2] . This antibody is most likely identical with the antibody labeled anti-CV-2 some years earlier [3, 4] . There is no distinguishable neurological syndrome related to the presence of anti-CRMP-5, but most patients suffer from peripheral neuropathy, including optic neuropathy or movement disorders [5] . Most cases are associated with small-cell lung cancer, but association with other tumors like thymoma has been reported as well [1] ( table 1 ). An association with germinal cell tumors has not been reported so far. These patients may have anti-Ma autoantibodies, a group of antineuronal nucleolar autoantibodies. We here describe a patient presenting with symptoms of a limbic encephalitis and choreiform dyskinesias associated with anti-CRMP-5 due to a testicular tumor. Received: September 29, 2006 Accepted: November 12, 2006 Published online: March 26, 2007
- Published
- 2007
- Full Text
- View/download PDF
9. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy
- Author
-
Frank Weber, Jens Kuhle, Uwe K. Zettl, Joerg Kraus, Andrew T. Chan, Michael Guger, Sandra Niendorf, Christoph Kleinschnitz, Michael Linnebank, Andreas Weishaupt, Sven Jarius, Wolfgang Hitzl, Georg Pilz, Sebastian Rauer, Martin Stangel, Florian Lauda, Christian Geis, Heinz Wiendl, Andrea Harrer, Joerg R. Weber, Brigitte Wildemann, Ilya Ayzenberg, Hayrettin Tumani, Manfred Uhr, Farmacologie en Toxicologie, RS: CARIM School for Cardiovascular Diseases, University of Zurich, and Harrer, A
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,intrathecal IgG ,Multiple Sclerosis ,Adolescent ,610 Medicine & health ,Context (language use) ,Antibodies, Monoclonal, Humanized ,cerebrospinal fluid ,Young Adult ,Immune system ,Cerebrospinal fluid ,Natalizumab ,medicine ,Humans ,B cell ,Aged ,Retrospective Studies ,B-Lymphocytes ,medicine.diagnostic_test ,Lumbar puncture ,business.industry ,Multiple sclerosis ,Progressive multifocal leukoencephalopathy ,Oligoclonal Bands ,Middle Aged ,medicine.disease ,10040 Clinic for Neurology ,2728 Neurology (clinical) ,medicine.anatomical_structure ,Neurology ,2808 Neurology ,Immunoglobulin G ,Antibody Formation ,Female ,Neurology (clinical) ,business ,medicine.drug - Abstract
Recently, the disappearance of oligoclonal bands (OCBs) from the cerebrospinal fluid (CSF) of a few natalizumab-treated patients with multiple sclerosis (MS) has been reported. This is interesting since CSF-restricted OCB are believed to persist in MS. We pooled CSF data from 14 MS centers to obtain an adequate sample size for investigating the suspected changes in central nervous system (CNS)-restricted humoral immune activities in the context of natalizumab therapy. In a retrospective chart analysis, CSF parameters of blood–CSF barrier integrity and intrathecal IgG production from 73 natalizumab-treated MS patients requiring a diagnostic puncture for exclusion of progressive multifocal leukoencephalopathy were compared with CSF data obtained earlier in the course of disease before natalizumab therapy. At the time of repeat lumbar puncture, local IgG production (according to Reibergram) was significantly reduced ( p < 0.0001) and OCB had disappeared in 16% of the patients. We therefore conclude that natalizumab therapy interferes with intrathecal antibody production at least in a significant number of patients.
- Published
- 2012
10. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis
- Author
-
Georg Pilz, Andrea Harrer, Joerg Kraus, Eugen Trinka, Stefan Golaszewski, Wolfgang Hitzl, Shahrzad Afazel, Katrin Oppermann, Max Einhaeupl, Elisabeth Haschke-Becher, Peter Wipfler, and Johann Sellner
- Subjects
Adult ,Male ,Time Factors ,Integrin alpha4 ,lcsh:Medicine ,Antibodies, Monoclonal, Humanized ,Flow cytometry ,Natalizumab ,Immune system ,Multiple Sclerosis, Relapsing-Remitting ,medicine ,Humans ,lcsh:Science ,Monoclonal antibody therapy ,Multidisciplinary ,medicine.diagnostic_test ,business.industry ,Progressive multifocal leukoencephalopathy ,Multiple sclerosis ,lcsh:R ,Natural killer T cell ,medicine.disease ,Flow Cytometry ,Antibodies, Neutralizing ,Lymphocyte Subsets ,Neurology ,Immunology ,Biomarker (medicine) ,Medicine ,lcsh:Q ,Female ,Clinical Immunology ,business ,medicine.drug ,Research Article - Abstract
Natalizumab is an effective monoclonal antibody therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS) and interferes with immune cell migration into the central nervous system by blocking the α(4) subunit of very-late activation antigen-4 (VLA-4). Although well tolerated and very effective, some patients still suffer from relapses in spite of natalizumab therapy or from unwanted side effects like progressive multifocal leukoencephalopathy (PML). In search of a routine-qualified biomarker on the effectiveness of natalizumab therapy we applied flow cytometry and analyzed natalizumab binding to α(4) and α(4) integrin surface levels on T-cells, B-cells, natural killer (NK) cells, and NKT cells from 26 RRMS patients under up to 72 weeks of therapy. Four-weekly infusions of natalizumab resulted in a significant and sustained increase of lymphocyte-bound natalizumab (p
- Published
- 2011
11. First detection of the Anaplasma phagocytophilum groEL-A genotype in man
- Author
-
Petra Apfalter, Elisabeth Haschke-Becher, Rainer Bernauer, Peter Strasser, Gunther Ladurner, Shahrzad Afazel-Saeedi, Anna-Maria Walleczek, and Joerg Kraus
- Subjects
Microbiology (medical) ,DNA, Bacterial ,Male ,Anaplasmosis ,Human granulocytic anaplasmosis ,Genotype ,macromolecular substances ,Polymerase Chain Reaction ,law.invention ,Bacterial Proteins ,law ,medicine ,Animals ,Humans ,Typing ,Genotyping ,Pathogen ,Polymerase chain reaction ,Aged ,Genetics ,biology ,Chaperonin 60 ,medicine.disease ,biology.organism_classification ,GroEL ,Anaplasma phagocytophilum ,Virology ,enzymes and coenzymes (carbohydrates) ,Infectious Diseases ,Blood ,biological sciences ,health occupations ,bacteria ,Female - Abstract
Summary Objective Human Granulocytic Anaplasmosis (HGA) is an emerging disease caused by the gram-negative bacterium Anaplasma phagocytophilum which is transmitted by ticks of the genus Ixodes ricinus . For molecular detection of the pathogen by PCR, a conserved portion of the groEL gene within the groESL operon is frequently used as a target. A single G/A polymorphism in this region allows to discriminate between two genotypes, groEL -G and groEL -A. Methods Total DNA from peripheral blood samples of two HGA patients was analysed by RealTime PCR, employing a protocol designed for genotyping groEL- G- and groEL- A variants of A. phagocytophilum . Results We confirmed two clinical cases of HGA by PCR; in one patient, and for the first time in a human host, the groEL -A variant was detected, in the other case the pathogen was recognised as the groEL -G variant, up to now representing the only genotype reported in man. Conclusions It is documented that HGA infections can be caused by two A. phagocytophilum groEL genotypes. At present, the preference of the A. phagocytophilum groEL -G genotype in humans remains unclear, as we describe the first patient with HGA caused by the groEL -A variant. For a conclusive interpretation, more data from HGA patients will be required.
- Published
- 2009
12. Current endovascular treatment of acute stroke and future aspects
- Author
-
Monika Killer, Gunther Ladurner, Joerg Kraus, and Alexander Kunz
- Subjects
medicine.medical_specialty ,Time Factors ,Brain Ischemia ,Central nervous system disease ,High morbidity ,Fibrinolytic Agents ,Time windows ,Drug Discovery ,medicine ,Animals ,Humans ,cardiovascular diseases ,Endovascular treatment ,Stroke ,Acute stroke ,Pharmacology ,Window of opportunity ,Vascular disease ,business.industry ,medicine.disease ,Surgery ,Tissue Plasminogen Activator ,Emergency medicine ,Acute Disease ,business - Abstract
Acute ischemic stroke remains a condition of high morbidity and mortality. Until now, the only established therapy has been intravenous (IV) tissue-type plasminogen activator (tPA). Only 3–10% of patients with acute ischemic stroke receive this treatment. On the basis of data from part 3 of the European Collaborative Acute Stroke Study (ECASS III), the time window for beneficial treatment of ischemic stroke with IV tPA has been extended from 3 to 4.5 h after the onset of stroke symptoms. Beyond that window of opportunity, and additionally to IV treatment, interventional stroke therapy has assumed an important role for the treatment of acute ischemic stroke. Currently, new promising pharmacological and mechanical treatment options are being established as routine procedures to achieve a further improved outcome for stroke patients.
- Published
- 2009
13. Bending strength and fractographic analysis of zinc tellurite glass modified optical fibers
- Author
-
Carlo Bruschi, Herbert Buerger, Enrico Chierici, Joerg Kraus, and Ivailo Gugov
- Subjects
symbols.namesake ,Fracture toughness ,Materials science ,Flexural strength ,Indentation ,Vickers hardness test ,symbols ,Fractography ,Young's modulus ,Composite material ,Cladding (fiber optics) ,Indentation hardness - Abstract
Single mode and multimode tellurite fibres were drawn from preforms of TZN composition (75TeO2 20ZnO 5Na2O) to which 2 mol-% of BaO or La2O3 had been added in the cladding, and their mechanical properties determined. Average bending strengths of 540 to 830 MPa were found after determination of the Young's modulus, which amounted to 46.3 GPa and 46.1 GPa for TZNB and TZNL, respectively. Compared to fluorozirconate fibres drawn previously under nearly the same conditions, average bending strength increased by more than 30 %. On aging in water, the strength of tellurite fibres with TZNL cladding remained unchanged even after 10 days. That of fluoride decreased by more than 50 % within 24 h. Fractographic analysis on fractured tellurite fibres yielded a mirror constant, M, of 1.017 MPa.m1/2. No difference was seen between aged and pristine fibres. By contrast, the mirror constant of fluoride fibre decreased by 10 % on aging. Vickers indentation on TZNL clad glass resulted in a Vickers microhardness, HV, of 3.18 GPa and a fracture toughness, KC, of 0.25 MPa.m1/2. Based on KC and glass structure, an attempt was made to relate fractographic results to the fractal geometry concept as proposed by Mecholsky.© (2002) COPYRIGHT SPIE--The International Society for Optical Engineering. Downloading of the abstract is permitted for personal use only.
- Published
- 2002
- Full Text
- View/download PDF
14. Contents Vol. 57, 2007
- Author
-
Daniele Imperiale, Juraj Sepčić, Ching-Po Lin, Bojana Brajenović-Milić, Soichi Okino, Toshiaki Hanafusa, Borut Peterlin, Yukitoshi Takahashi, G. Bergendal, Lucia Appendino, S. Fredrikson, Miljenko Kapović, A. Gomez de la Cámara, Darius G. Nabavi, O. Almkvist, Franz Blaes, Giorgio Marietti, Joerg Kraus, Luca Lovrečić, Jochen Spiess, Robert Christian Wolf, Toshiaki Mito, Kuniko Matsuyama, C. Stöllberger, Nada Starčević-Čizmarević, Neeraj Kumar, Renaud Du Pasquier, Giulia Guastamacchia, Carlo Buffa, Sergio Duca, Joseph E. Thomas, Christoph Kellinghaus, F. Bermejo, J.M. Guerra, Tohru Kuramitsu, Fumiharu Kimura, Saša Šega Jazbec, Masafumi Uchino, Muneyoshi Tagami, Wolf Rüdiger Schäbitz, Masahito Yamada, M. Hofer, Smiljana Ristić, Keiichi Shinoda, Nora Lee, Yu-Ming Chuang, Masakazu Sugino, Paul D. Thompson, Cristiana Atzori, Mitsuaki Hosoya, Po-Jung Pan, J. Finsterer, J.A. Molina, J.F. Varona, Chih-Yang Liu, Hideto Nakajima, Simon Ishida, Christopher J. Boes, Nenad Vasic, J.M.S. Pearce, Roman Huber, Jun Nomoto, Alessandra Romito, Jerry W. Swanson, Kazuo Iwasa, Tsuyoshi Hamaguchi, Daisuke Haga, and Daisuke Furutama
- Subjects
Neurology ,Neurology (clinical) - Published
- 2007
- Full Text
- View/download PDF
15. Subject Index Vol. 57, 2007
- Author
-
Christopher J. Boes, Darius Günter Nabavi, Nenad Vasic, Soichi Okino, J.M.S. Pearce, Daniele Imperiale, Juraj Sepčić, J.F. Varona, Hideto Nakajima, Bojana Brajenović-Milić, G. Bergendal, Toshiaki Mito, Lucia Appendino, Joerg Kraus, Fumiharu Kimura, Robert Christian Wolf, Renaud Du Pasquier, O. Almkvist, Franz Blaes, Kuniko Matsuyama, Neeraj Kumar, Masahito Yamada, S. Fredrikson, M. Hofer, Kazuo Iwasa, J.M. Guerra, Sergio Duca, Yu-Ming Chuang, Daisuke Furutama, Nada Starčević-Čizmarević, Jochen Spiess, A. Gomez de la Cámara, Po-Jung Pan, Giulia Guastamacchia, Carlo Buffa, J. Finsterer, Luca Lovrečić, Toshiaki Hanafusa, Tohru Kuramitsu, Masafumi Uchino, Roman Huber, Tsuyoshi Hamaguchi, Simon Ishida, Smiljana Ristić, Jun Nomoto, Keiichi Shinoda, Nora Lee, J.A. Molina, Chih-Yang Liu, Alessandra Romito, Masakazu Sugino, Paul D. Thompson, Joseph E. Thomas, Ching-Po Lin, Miljenko Kapović, Cristiana Atzori, Mitsuaki Hosoya, Giorgio Marietti, C. Stöllberger, Saša Šega Jazbec, Wolf R. Schäbitz, Muneyoshi Tagami, Daisuke Haga, Jerry W. Swanson, F. Bermejo, Christoph Kellinghaus, Borut Peterlin, and Yukitoshi Takahashi
- Subjects
Gerontology ,Index (economics) ,Neurology ,Subject (documents) ,Neurology (clinical) ,Psychology - Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.